NCT05162066

Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)

An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects With Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: BioCryst Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study was to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.

Conditions

• Complement 3 Glomerulopathy
• Immunoglobulin A Nephropathy
• Membranous Nephropathy

Interventions

Type	Name	Description
DRUG	BCX9930	Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily

Timeline

• Start date: 2022-02-18
• Primary completion: 2022-09-23
• Completion: 2022-09-23
• First posted: 2021-12-17
• Last updated: 2024-05-02
• Results posted: 2024-05-02

Locations

11 sites across 4 countries: France, Italy, Spain, United Kingdom

Regulatory

• FDA-regulated drug study